Anti-Hypertensive Drugs - Asia

Asia

The projected revenue in the Anti-Hypertensive Drugs market in Asia is expected to reach €4.26bn in 2024.
It is anticipated that there will be an annual growth rate (CAGR 2024-2029) of 0.51%, leading to a market volume of €4.37bn by 2029.
When comparing globally, United States is expected to generate the highest revenue, with €11,400.00m in 2024.
In Japan, the market for anti-hypertensive drugs is dominated by a strong preference for traditional herbal remedies over pharmaceutical options.

Key regions: Japan, India, Italy, Brazil, South Korea

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Asia has been increasing steadily over the years.

Customer preferences: Customers in Asia have shown a preference for generic drugs due to their lower cost compared to branded drugs. This preference has been driven by the high out-of-pocket expenses for healthcare in the region. Additionally, customers have shown a preference for combination drugs that offer a more convenient treatment option.

Trends in the market: In China, the Anti-Hypertensive Drugs market has been growing rapidly due to the increasing prevalence of hypertension in the country. The Chinese government has been promoting the use of generic drugs to reduce healthcare costs, which has led to increased competition among manufacturers. In Japan, the market has been driven by the introduction of new drugs and the increasing use of combination therapies. South Korea has seen a shift towards combination therapies as well, with a focus on fixed-dose combinations.

Local special circumstances: In India, the market for Anti-Hypertensive Drugs has been driven by the high prevalence of hypertension in the country. However, the market is highly fragmented with a large number of small manufacturers. This has led to quality control issues and a lack of standardization in the market. In Indonesia, the market is dominated by local manufacturers who have a strong distribution network in the country. This has made it difficult for international manufacturers to enter the market.

Underlying macroeconomic factors: The increasing prevalence of hypertension in Asia has been driven by changing lifestyles and an aging population. Rapid urbanization and the adoption of a Western diet have also contributed to the rise in hypertension cases. Additionally, the increasing focus on preventive healthcare in the region has led to more people being diagnosed with hypertension and starting treatment. The high out-of-pocket expenses for healthcare in the region have also driven demand for lower cost generic drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.